

News From



**IMALUX CORPORATION
PRESS ANNOUNCEMENT
FOR IMMEDIATE RELEASE**

Contact: Nancy Tresser, MD, MBA at (216) 502-0755 x1002
or email ntresser@imalux.com

**IMALUX COLLABORATES WITH PREVENTATIVE ONCOLOGY
INTERNATIONAL™ IN STUDY OF CERVICAL CANCER IN CHINA**

Cleveland, Ohio, January 10, 2008 – Dr. Jerome Belinson, a leading researcher in gynecological cancers, and his team from Preventative Oncology International™ (POI), along with Dr. Nancy Tresser, Chief Medical Officer of Imalux Corporation, recently collaborated in a controlled 299 patient study of cervical cancer in China.

Cervical cancer is the second greatest cause of cancer deaths in women world-wide. It is directly linked to the high-risk types of the Human Papillomavirus (HPV). While the current standard for cervical cancer diagnosis in the US is based upon the Pap test, the link between cervical cancer and HPV has made it possible to identify patients at high risk of cervical cancer by testing for the HPV virus.

The IRB approved “Study of the Diagnostic Efficacy of ‘Real Time’ Optical Coherence Tomography (OCT) in the Management of Pre-Invasive and Invasive Neoplasia of the Uterine Cervix” was conducted at the Peking University Shenzhen Hospital in December. The study was done to evaluate the use of OCT during cervix examinations. 1200 OCT images are being compared to pathologic findings to determine the accuracy of OCT in this application. A second collaborative study is planned for April in Guizhou, China. A successful outcome from these studies could lead to early cervical cancer detection and definitive treatment during a single office visit (single episode of care). According to Dr. Tresser, “these studies are proof positive of the progress being made by Imalux and POI in our mutual goal to improve women’s health world wide.”

Imalux is a Cleveland-based corporation that is focused on the clinical validation and commercialization of Optical Coherence Tomography technology originally developed at the Institute of Applied Physics of the Russian Academy of Sciences, one of the main progenitors of OCT technology worldwide.

The Company’s Niris Imaging System provides real-time, high spatial resolution, two-dimensional, cross-sectional depth visualization of tissue microstructure. The compact,

point-of-care System creates images utilizing harmless near infrared light. The spatial resolution of the System is on the order of 0.01 mm, surpassing conventional ultrasound imaging by an order of magnitude. Nirix is currently being used at leading worldwide institutions by clinicians and researchers in numerous clinical validation programs, principally in the field of urology, with emphasis on prostate and bladder procedures. For more information about Imalux see www.imalux.com.

Preventive Oncology International™ (POI) is an international non-profit organization that blends humanitarian work with scientific investigation. Since its founding in 1997, it has been the specific objective of POI to transplant as well as develop techniques of high quality cervical cancer screening, diagnosis and treatment, to the developing countries and other low resource areas. POI has already completed HPV and cervical cancer screening studies in Mexico and Dominican Republic, as well as both urban and rural sites in China. For more information on POI see <http://www.preventiveoncologyinternational.org>.

